(Q36201691)

12 August 2017

1 reference

title

Carbohydrate vaccines as immunotherapy for cancer (English)

1 reference

12 August 2017

1 reference

Susan F Slovin

1

1 reference

PubMed ID

16033538

12 August 2017

Stacy J Keding

series ordinal

2

1 reference

PubMed ID

16033538

12 August 2017

Govind Ragupathi

series ordinal

3

1 reference

12 August 2017

1 August 2005

1 reference

Immunology & Cell Biology

12 August 2017

1 reference

12 August 2017

83

1 reference

12 August 2017

4

1 reference

12 August 2017

418-428

1 reference

THE RESULTS OF THE SERUM TREATMENT IN THIRTEEN HUNDRED CASES OF EPIDEMIC MENINGITIS

12 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

THE SOLUBLE SPECIFIC SUBSTANCE OF PNEUMOCOCCUS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

Constructing an adenocarcinoma vaccine: immunization of mice with synthetic KH-1 nonasaccharide stimulates anti-KH-1 and anti-Le(y) antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

Principles of mucin architecture: structural studies on synthetic glycopeptides bearing clustered mono-, di-, tri-, and hexasaccharide glycodomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

Probing cell-surface architecture through synthesis: an NMR-determined structural motif for tumor-associated mucins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

Marine tumor vaccine carriers: structure of the molluscan hemocyanins KLH and htH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

Ectopic dendrites occur only on cortical pyramidal cells containing elevated GM2 ganglioside in alpha-mannosidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

Approaches to Augmenting the Immunogenicity of Melanoma Gangliosides: From Whole Melanoma Cells to Ganglioside‐KLH Conjugate Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

Immunogenicity of membrane-bound gangliosides in viable whole-cell vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

Role of Gangliosides in Active Immunotherapy with Melanoma Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

Immunization of mice with fucosyl-GM1 conjugated with keyhole limpet hemocyanin results in antibodies against human small-cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

Prospects for total synthesis: a vision for a totally synthetic vaccine targeting epithelial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2005.01350.X

10.1111/J.1440-1711.2005.01350.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

16033538